ST Pharm Co.,Ltd. (KOSDAQ:237690)
102,000
+3,300 (3.34%)
Nov 20, 2025, 3:30 PM KST
ST Pharm Revenue
ST Pharm had revenue of 68.25B KRW in the quarter ending June 30, 2025, with 53.06% growth. This brings the company's revenue in the last twelve months to 298.11B, up 9.24% year-over-year. In the year 2024, ST Pharm had annual revenue of 273.75B, down -3.94%.
Revenue (ttm)
298.11B
Revenue Growth
+9.24%
P/S Ratio
6.85
Revenue / Employee
455.13M
Employees
655
Market Cap
2.04T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 273.75B | -11.24B | -3.94% |
| Dec 31, 2023 | 284.99B | 35.67B | 14.31% |
| Dec 31, 2022 | 249.32B | 83.68B | 50.52% |
| Dec 31, 2021 | 165.64B | 41.53B | 33.47% |
| Dec 31, 2020 | 124.11B | 30.85B | 33.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |